MedTrace Logo

Statin and Epidural Steroid Injection

NCT02162940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2014-06-13

No results posted yet for this study

Summary

The impact of statin use on response to epidural steroid injections remains unknown and may well increase the effect considering the substantial anti-inflammatory properties. We thus tested the primary hypothesis that patients taking statins before and after the procedure will have lower VAS scores compared to patients not on statins. Secondarily we tested the hypothesis that statin users will have improved quality of life evaluated with Short Form 36 (SF 36).

Conditions

  • Low Back Pain After Epidural Steroid Injection
  • Quality of Life After Epidural Steroid Injection

Interventions

OTHER

Visual analogue score

Visual analogue score vas used to evaluate pain.

OTHER

The SF 36 test

The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.

Sponsors & Collaborators

  • Aydin Adnan Menderes University

    lead OTHER

Principal Investigators

  • Osman Nuri Aydın, Prof · Adnan Menderes University Medical Faculty Algology Department

  • Banu Taşdemir, Asist Dr · Adnan Menderes University Medical Faculty Anesthesiology and Reanimation Department

  • Fabrizio Galimberti, Medical Student · Cleveland ClinicLernerCollege of Medicine, Cleveland, Ohio

  • Alparslan Turan, Associate Prof · Department of Outcomes Research, Cleveland Clinic

  • Sinem Sari, Assist Prof · Adnan Menderes University Medical Faculty Anesthesiology and Reanimation Department

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02162940 on ClinicalTrials.gov